Prevalence of small bowel bacterial overgrowth in patients with functional dyspepsia: a meta-analysis

Kucheryavy, Yu.A.; Andreev, D. N.; Маев, И. В.

doi:10.26442/00403660.2020.12.200433

Cited by 8 publications

(3 citation statements)

References 43 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Несмотря на гетерогенность паттерна моторных нарушений, общими для большинства ФЗ ЖКТ являются связь симптоматики с тревогой и депрессией, наличие висцеральной гиперчувствительности, нередкий постинфекционный генез заболевания, изменения микробиоты ЖКТ (ассоциация с синдромом избыточного бактериального роста в тонкой кишке), повышение проницаемости слизистой оболочки кишечника и воспаление слизистой оболочки низкой степени активности (от англ. low-grade inflammation) [22][23][24][25][26][27]. Эффективная фармакотерапия ФЗ ЖКТ остается трудной задачей в условиях рутинной клинической практики, так как у многих пациентов наблюдается субоптимальный комплаенс, что диктует необходимость использования лекарственных форм препаратов с большей дозой действующего вещества или пролонгированным высвобождением [18,28].…”

Section: Discussionunclassified

Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study

Andreev

Николаеви²,

Маев

et al. 2021

Terapevticheskii arkhiv

Self Cite

View full text Add to dashboard Cite

Aim. Evaluation of the practice of using trimebutine (tablets, 300 mg, extended release), for the treatment of patients with functional gastrointestinal disorders (FGID) in primary health care. Materials and methods. A prospective observational multicenter non-interventional study was carried out, which included patients of both sexes aged 18 to 60 years with a verified diagnosis of functional gastrointestinal disorders (functional dyspepsia, irritable bowel syndrome, biliary tract dysfunction, sphincter of Oddi dysfunction, postcholecystectomy syndrome). Trimebutine was prescribed in accordance with the instructions for medical use: orally, 300 mg twice per day for 28 days. The severity of simptoms was evaluated by five-point rating scale. Results. The study included 4433 patients, the per protocol sample consisted of 3831 people. The proportion of patients with a significant decrease in the severity of abdominal pain after treatment was 74.73% (95% confidence interval CI 73.3276.11). At the and of the study a statistically significant decrease in the severity of FGID` simptoms was observed: epigastric pain/burning (mean score at the 1st visit was 1.21 [95% CI 1.181.25], at the 2nd visit 0.22 [95% CI 0.20.23]; p0.001), abdominal pain (1st visit 2.01 [95% CI 1.982.04), 2nd visit 0.33 [95% CI 0.310.35]; p0.001), biliary pain (1st visit 1.22 [95% CI 1.181.26], 2nd visit 0.2 [95% CI 0.190.22]; p0.001), postprandial fullness and early satiation (1st visit 1.29 [95% CI 1.251.32], 2nd visit 0.21 [95% CI 0.190.22]; p0.001), severity of heartburn (1st visit 0.92 [95% CI 0.880.95], 2nd visit 0.18 [95% CI 0.170.20]; p0.001), belching (1st visit 1.13 [95% CI 1.091.16], 2nd visit 0.22 [95% CI 0.210.24]; p0.001), as well as abdominal distention (1st visit 1.99 (95% CI 1, 96, 2.03), 2nd visit 0.43 [95% CI 0.410.45]; p0.001). Conclusion. The present prospective observational multicenter non-interventional study has demonstrated that trimebutine is an effective approach to treating FGID.

show abstract

Section: Discussionunclassified

Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study

Andreev

Николаеви²,

Маев

et al. 2021

Terapevticheskii arkhiv

Self Cite

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of seven studies found that the prevalence of SIBO in functional dyspepsia is 34.7% (95%CI: 24.8%-45.4%)[ 26 ]. Another meta-analysis found SIBO prevalence in functional dyspepsia to be significantly higher using the LBT (53.4%, 95%CI: 33.9%-71.9%) compared with the GBT (17.2%, 95%CI: 8.6%-31.6%).…”

Section: Functional Digestive Diseasesmentioning

confidence: 99%

Epidemiology of small intestinal bacterial overgrowth

Efremova,

Maslennikov,

Poluektova

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the bacterial content of the small intestine above normal values. The presence of SIBO is detected in 33.8% of patients with gastroenterological complaints who underwent a breath test, and is significantly associated with smoking, bloating, abdominal pain, and anemia. Proton pump inhibitor therapy is a significant risk factor for SIBO. The risk of SIBO increases with age and does not depend on gender or race. SIBO complicates the course of a number of diseases and may be of pathogenetic significance in the development of their symptoms. SIBO is significantly associated with functional dyspepsia, irritable bowel syndrome, functional abdominal bloating, functional constipation, functional diarrhea, short bowel syndrome, chronic intestinal pseudo-obstruction, lactase deficiency, diverticular and celiac diseases, ulcerative colitis, Crohn’s disease, cirrhosis, metabolic-associated fatty liver disease (MAFLD), primary biliary cholangitis, gastroparesis, pancreatitis, cystic fibrosis, gallstone disease, diabetes, hypothyroidism, hyperlipidemia, acromegaly, multiple sclerosis, autism, Parkinson’s disease, systemic sclerosis, spondylarthropathy, fibromyalgia, asthma, heart failure, and other diseases. The development of SIBO is often associated with a slowdown in orocecal transit time that decreases the normal clearance of bacteria from the small intestine. The slowdown of this transit may be due to motor dysfunction of the intestine in diseases of the gut, autonomic diabetic polyneuropathy, and portal hypertension, or a decrease in the motor-stimulating influence of thyroid hormones. In a number of diseases, including cirrhosis, MAFLD, diabetes, and pancreatitis, an association was found between disease severity and the presence of SIBO. Further work on the effect of SIBO eradication on the condition and prognosis of patients with various diseases is required.

show abstract

“…In a meta-analysis of 7 studies involving 1248 patients, the pooled incidence of SIBO in patients with FD was 34.73% (95% CI: 24.807-45.380). When a study that examined the incidence of SIBO in patients with refractory FD was excluded from the metaanalysis, the pooled prevalence was 38.98% (95% CI: 28.964-49.490) [11].…”

mentioning

confidence: 99%

Cross-Section of Functional Diseases of the Gastrointestinal Tract: Focus on Disorders of The Motor Function of the Digestive System

2023

J Urol Ren Dis

View full text Add to dashboard Cite

Functional diseases of the digestive system (FZOP) is a group of disorders characterized by a violation of the interaction between the central (brain) and peripheral parts of the nervous system, which ensures the activity of the organs of the gastrointestinal tract (GIT). Overlap-syndrome -a syndrome of overlapping functional diseases of the digestive system, in which two or more disorders are combined, united by common pathogenetic mechanisms. The goal is to identify the role of gastrointestinal motility disorders in the intersection of functional diseases of the gastrointestinal tract -functional dyspepsia and GERD. Results and discussion. Identified disorders of motor function include hypomotor dyskinesia of the stomach (77.5%), small intestine (35%) and right colon (53.8%). The results indicate the development of SIBO in the small intestine and dysbiosis in the ascending colon intestines. The predominant spastic activity of the right and left parts of the colon indicates the development of constipation.

show abstract

Prevalence of small bowel bacterial overgrowth in patients with functional dyspepsia: a meta-analysis

Cited by 8 publications

References 43 publications

Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study

Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study

Epidemiology of small intestinal bacterial overgrowth

Cross-Section of Functional Diseases of the Gastrointestinal Tract: Focus on Disorders of The Motor Function of the Digestive System

Contact Info

Product

Resources

About